person
as of 2026-07-01Rituparna Maiti, MD
ORCID 0000-0003-4063-9178
at a glance
Roles: Study Director, Author
KOL signal score 8
3 publications · 1 high-value
Cross-drug reach: 3 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
AIIMS Bhubaneswar
Roles
Study Director, Author
KOL signal
8
Publications
3 (1 high-value)
Trial investigator
no
Publishes on
3 drugs
Trials led
1
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
NCT06501339Phase 4Not Yet Recruiting
Publications & congress
3
Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial.
Journal of psychiatric research · 2024 · high-value
Lumateperone as an alternative to clozapine in treatment-resistant schizophrenia: Insights from a quantitative systems pharmacology model.
The Journal of pharmacology and experimental therapeutics · 2026
A Bayesian network meta-analysis of randomized controlled trials comparing the efficacy and safety of cholinergic modulators in schizophrenia.
Journal of psychopharmacology (Oxford, England) · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on